Role of Patient Sorting in Avoidable Hospital Stays in Medicare Advantage vs Traditional Medicare.


Journal

JAMA health forum
ISSN: 2689-0186
Titre abrégé: JAMA Health Forum
Pays: United States
ID NLM: 101769500

Informations de publication

Date de publication:
03 Nov 2023
Historique:
medline: 13 11 2023
pubmed: 10 11 2023
entrez: 10 11 2023
Statut: epublish

Résumé

Unlike traditional Medicare (TM), Medicare Advantage (MA) plans limit in-network care to a specific network of Medicare clinicians. MA plans thus play a role in sorting patients to a subset of clinicians. It is unknown whether the performance of physicians who treat MA and TM beneficiaries is different. To examine whether avoidable hospital stay differences between MA and TM can be explained by the primary care clinicians who treat MA and TM beneficiaries. This was a cross-sectional study of a nationally representative sample of MA and TM beneficiaries in 2019 with any of 5 chronic ambulatory care-sensitive conditions (ACSCs). The relative risk (RR) of avoidable hospital stays in MA compared with TM was estimated with inverse probability of treatment-weighted Poisson regression, both without and with clinician fixed effects. The degree to which the estimated MA vs TM difference could be explained by patient sorting was calculated by comparing the 2 RR estimates. Data were analyzed between February 2022 and April 2023. Enrollment in MA. Whether a beneficiary had avoidable hospital stays in 2019 due to any of the ACSCs. Avoidable hospital stays included both hospitalizations and observation stays. The study sample comprised 1 323 481 MA beneficiaries (mean [SD] age, 75.4 [7.0] years; 56.9% women; 69.3% White) and 1 965 863 TM beneficiaries (mean [SD] age, 75.9 [7.4] years; 57.1% women; 82.5% White). When controlling for the primary care clinician, the RR of avoidable hospital stays in MA vs TM changed by 2.6 percentage points (95% CI, 1.72-3.50; P < .001), suggesting that compared with TM beneficiaries, MA beneficiaries saw clinicians with lower rates of avoidable hospital stays. This effect size was statistically significant to explain the 2% lower rate of avoidable hospital stays in MA than in TM. In this cross-sectional study of MA and TM beneficiaries, the lower rate of avoidable hospital stays among MA beneficiaries than TM beneficiaries was attributable to MA beneficiaries visiting clinicians with lower rates of avoidable hospital stays. The patient sorting that occurs in MA plays a critical role in the lower rates of avoidable hospital stays compared with TM.

Identifiants

pubmed: 37948062
pii: 2811769
doi: 10.1001/jamahealthforum.2023.3931
pmc: PMC10638641
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e233931

Subventions

Organisme : AHRQ HHS
ID : T32 HS000029
Pays : United States

Références

Med Care. 2020 Jan;58(1):e1-e8
pubmed: 31688554
Health Serv Res. 2018 Apr;53(2):859-878
pubmed: 28560732
JAMA Health Forum. 2021 Dec 10;2(12):e214001
pubmed: 35977297
Med Care. 2021 Nov 1;59(11):989-996
pubmed: 34432767
Health Serv Res. 2022 Jun;57(3):537-547
pubmed: 34806171
J Gen Intern Med. 2022 Feb;37(2):488-491
pubmed: 33469747
J Health Econ. 2016 Dec;50:86-98
pubmed: 27697699
Health Aff (Millwood). 2023 Apr;42(4):459-469
pubmed: 37011314
Health Aff (Millwood). 2021 Jun;40(6):937-944
pubmed: 34097516
Am J Manag Care. 2016 Jun;22(6):420-5
pubmed: 27355809
Am J Med Qual. 2018 Jan/Feb;33(1):58-64
pubmed: 28388857
JAMA Health Forum. 2023 Feb 3;4(2):e225530
pubmed: 36826828
JAMA Health Forum. 2021 Jul 30;2(7):e211816
pubmed: 35977214
Health Serv Res. 2022 Aug;57(4):957-962
pubmed: 35411550
Med Care. 2021 Feb 1;59(2):96-100
pubmed: 32925467
Am J Epidemiol. 2004 Apr 1;159(7):702-6
pubmed: 15033648

Auteurs

Jianhui Frank Xu (JF)

Department of Health Policy and Management, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland.

Kelly E Anderson (KE)

Department of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora.

Angela Liu (A)

Department of Health Policy and Management, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland.

Brian J Miller (BJ)

Division of Hospital Medicine, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
American Enterprise Institute, Washington, DC.

Daniel Polsky (D)

Department of Health Policy and Management, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland.
Carey Business School, Johns Hopkins University, Baltimore, Maryland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH